Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use…
Rhythm Pharmaceuticals, Inc.-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access designation for hypothalamic obesity comes in addition to…
Lire la suite...
Lire la suite...